FDA Commissioner-Nominee Gottlieb Pressed More On Drug Development Than Industry Ties
Scott Gottlieb's industry connections were expected to be a major focus of his US Senate confirmation hearing. However, our analysis of the questions asked show drug development was the top priority.
You may also be interested in...
Former deputy commissioner will also likely push increased use of biomarkers and more flexibility in off-label communication, among other reforms.
Azar says ACIP’s prioritization recommendations should carry weight, but states will be final arbiter of who is vaccinated.
As distribution of Regeneron’s monoclonal antibody treatment for coronavirus begins, OWS officials worry about provider confusion with Lilly’s product due to differences in preparation and administration.